Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/05/01 02:55:25」(JST)

wiki en

Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic^[2] compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive^[3] medication in Germany, France, Italy and other countries.

References

^ Mutschler, Edited by Rainer F. Greger, H. Knauf, E. Mutschler (1995). Diuretics. Handbook of Experimental Pharmacology (Том 117). Berlin, Heidelberg: Springer Science & Business Media, 2012. p. 517. ISBN 364279565X.
^ Musini, V. M.; Wright, J. M.; Bassett, K.; Jauca, C. D. (2009). Musini, Vijaya M, ed. "Blood pressure lowering efficacy of loop diuretics for primary hypertension". The Cochrane Library (4): CD003825. doi:10.1002/14651858.CD003825.pub2. PMID 19821314.
^ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

W.Merkel, D.Bormann, D.Mania, R.Muschaweck and M.Hropot, Eur. J. Med. Chem.-Chim.Ther. 11,399 (1976).
W.Merkel, D.Mania and D.Bormann, Liebigs Ann. Chem. 461 (1979).

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

English Journal

Blood pressure-lowering efficacy of loop diuretics for primary hypertension.

Musini VM1, Rezapour P, Wright JM, Bassett K, Jauca CD.
The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2015 May 22;(5):CD003825. doi: 10.1002/14651858.CD003825.pub4.
BACKGROUND: Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity. Loop diuretics are indicated and used to treat hypertension, but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reduc
PMID 26000442

Loop diuretics are open-channel blockers of the cystic fibrosis transmembrane conductance regulator with distinct kinetics.

Ju M1, Scott-Ward TS, Liu J, Khuituan P, Li H, Cai Z, Husbands SM, Sheppard DN.
British journal of pharmacology.Br J Pharmacol.2014 Jan;171(1):265-78. doi: 10.1111/bph.12458.
BACKGROUND AND PURPOSE: Loop diuretics are widely used to inhibit the Na(+), K(+), 2Cl(-) co-transporter, but they also inhibit the cystic fibrosis transmembrane conductance regulator (CFTR) Cl(-) channel. Here, we investigated the mechanism of CFTR inhibition by loop diuretics and explored the effe
PMID 24117047

Blood pressure lowering efficacy of loop diuretics for primary hypertension.

Musini VM1, Rezapour P, Wright JM, Bassett K, Jauca CD.
The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2012 Aug 15;(8):CD003825. doi: 10.1002/14651858.CD003825.pub3.
BACKGROUND: Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity. Loop diuretics are indicated and used as antihypertensive drugs but a systematic review of their blood pressure lowering efficacy or effectiveness in terms of re
PMID 22895937

Japanese Journal

Micellar electrokinetic chromatography as a fast screening method for the determination of the doping agents furosemide and piretanide in urine

Journal of chromatography. B, Biomedical sciences and applications 688(1), 71-78, 1997-01-10
NAID 10024510651

Dissolution phenomenon of the Piretanide Amorphous Form Involving phase Change

Chemical & pharmaceutical bulletin 44(11), 2111-2115, 1996-11-15
NAID 110003631822

Preparation of Amorphous and Polymorph Piretanide and Their Physicochemical Properties and Solubilities

Chemical & pharmaceutical bulletin 44(8), 1614-1617, 1996-08-15
NAID 110003632133

「ピレタニド」

Piretanide
Systematic (IUPAC) name
	3-(aminosulfonyl)-4-phenoxy-5-pyrrolidin-1-ylbenzoic acid
Clinical data
Trade names	Arelix, Eurelix, Tauliz
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
Legal status
Legal status	℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~90%
Protein binding	96%
Metabolism	not identified
Excretion	Urine (60%), feces (40%)
Identifiers
CAS Number	55837-27-9
ATC code	C03CA03 (WHO)
PubChem	CID 4849
IUPHAR/BPS	4742
DrugBank	DB02925
ChemSpider	4683
UNII	DQ6KK6GV93
KEGG	D01634
Chemical data
Formula	C17H18N2O5S
Molar mass	362.40 g/mol
	SMILES C1CCN(C1)C2=C(C(=CC(=C2)C(=O)O)S(=O)(=O)N)OC3=CC=CC=C3 ;
	InChI InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23) ; Key:UJEWTUDSLQGTOA-UHFFFAOYSA-N ;
(what is this?) (verify)

　　[★]

英: piretanide
商: アレリックス

[1] Mutschler, Edited by Rainer F. Greger, H. Knauf, E. Mutschler (1995). Diuretics. Handbook of Experimental Pharmacology (Том 117). Berlin, Heidelberg: Springer Science & Business Media, 2012. p. 517. ISBN 364279565X.

[2] Musini, V. M.; Wright, J. M.; Bassett, K.; Jauca, C. D. (2009). Musini, Vijaya M, ed. "Blood pressure lowering efficacy of loop diuretics for primary hypertension". The Cochrane Library (4): CD003825. doi:10.1002/14651858.CD003825.pub2. PMID 19821314.

[AustriaCodex-3] Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.

匿名

検索

案内

案内

piretanide